Risk Management for Aseptic Processing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Risk Management for Aseptic Processing
The author discusses the risks involved with aseptic processing, methods and tools used to identify and control risk, and regulatory guidelines relevant to the risk-management process.

Pharmaceutical Technology

Table I: Sample FMEA for fill line change over.
Failure mode and effects analysis. Failure mode and effects analysis (FMEA) is one of the most commonly used methods for pharmaceutical risk assessment. It is a team-based structured risk assessment method that can assign a numerical risk priority number based on relative perceived risk. A FMEA is dependent on the expertise of the team members (see Table I).

Hazard analysis and critical control points. Hazard analysis and critical control points (HACCP) is a tool mandated by FDA's Center for Food Safety and Applied Nutrition for use in the seafood industry and other food processing industries. Its use in the pharmaceutical industry was described in detail by the World Health Organization (WHO) in 2003 (5). The seven principles of HACCP include:

  • Conduct a hazard analysis
  • Determine the critical control points (CCPs)
  • Establish critical limits
  • Establish a system to monitor control of the CCP
  • Establish the corrective action to be taken when monitoring indicates that a particular CCP is not under control
  • Establish procedures for verification to confirm that the HACCP system is working effectively
  • Establish documentation concerning all procedures and records appropriate to these principles and their application.

Table II: HACCP worksheet (adapted from FDA CFSAN website).
Table II illustrates an HACCP worksheet for the filling of product into vials for a hypothetical biotech company.

Fault tree analysis. Fault tree analysis (FTA) is a risk-assessment method that begins with a failure event, and uses logic diagrams to determine the sequence of events required to cause the failure. FTA is frequently used as a design tool for critical systems. FTA can be used with other tools such as FMEA to ensure all failure modes are included and to develop estimates of the frequency of a particular failure mode.

This tool is excellent for equipment design and commissioning, for determining procedural controls needed to prevent a failure event, and for determining qualification and control strategies. With modification, it can also be used to assign probabilities to each failure mode.

The limitation of this tool is that it requires a large amount of time and effort to construct properly; it can expand rapidly as more detail is added. It is more suitable for large, complex systems than for simple systems because of the time and effort required.

FTA involves the following steps:

  • Define the failure (undesired event) to study
  • Gain knowledge of the system—gather a team of experts to analyze the system
  • Construct the fault tree
  • Evaluate the fault tree
  • Develop control strategies for the identified hazards.

Figure 3: Fault tree analysis diagram. (FIGURE 3 IS COURTESY OF THE AUTHOR)
Figure 3 shows a partial fault tree diagram for a critical failure—cross-contamination between two products. The top event represents the failure. Each subsequent level is connected by a logic gate (AND, OR, etc.). As shown in this figure, a fault tree diagram can grow rapidly and can become quite complex.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here